In the study, patients received either 12 weeks of treatment with antibiotics and a one-time infusion of bezlotoxumab, which is designed to block the ability of a toxin to bind to cells, or they received 12 weeks of treatment with antibiotics and a placebo.
Fifteen percent of the patients in the group that received that bezlotoxumab infusion experienced a recurrent C. diff infection, compared to 25 percent of those who received just antibiotics and the placebo.
Following the study, Merck & Co. announced plans to file for regulatory approval of bezlotoxumab, before the end of the year. Merck & Co. licensed the antibody from Massachusetts Biologic Laboratories and Medarex, now owned by Bristol-Myers Squibb.
More articles on C. diff:
C. diff pesticide found ineffective, EPA takes action
Abnormal vitals and blood tests linked to C. diff complications
C. diff is over diagnosed by popular molecular tests, study finds
